Morgan Stanley analyst Jeffrey Hung ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change

Acadia Pharma (ACAD) Stock Soars on Positive Rett Syndrome Results, Analysts Still Not ConvincedDecember 7, 2021 8:17 AM Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Goldman SachsDecember 7, 2021 6:39 AM Acadia Pharmaceuticals (ACAD) PT Raised to $26 at Mizuho SecuritiesDecember 7, 2021 6:30 AM Acadia’s (ACAD) Rett Syndrome Data Adequate for Approval, Stock Gains Are Justified - AnalystDecember 7, 2021 6:14 AM